Bildkälla: Stockfoto

Cantargia Q2 2023: CAN10 Approaching the Clinic - Redeye

Redeye comments on Cantargia’s second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.

Redeye comments on Cantargia’s second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.
Börsvärldens nyhetsbrev
ANNONSER